EVENTS | VIEW CALENDAR
SeraCare Life Sciences acquires KPL
MILFORD, Mass.—SeraCare Life Sciences, which deals in life science products for the diagnostic industry, has acquired Kirkegaard & Perry Laboratories (KPL), which it describes as "a leading provider of antibodies and related reagents for the diagnostic and life sciences markets."
With the acquisition, SeraCare is expanding its portfolio of products designed to help diagnostic researchers develop innovative in-vitro diagnostic assays through both off-the-shelf products and custom antibody design.
"The diagnostics industry requires high-quality materials for use in assay design, development of components for regulated kits, and validation of these products as they move from the laboratory to the clinic," said Charles Mamrak, CEO of SeraCare. "SeraCare strives to facilitate its customers' product development efforts, allowing researchers to focus on the science, specifically the design and launch of cutting- edge new assays. The addition of KPL will enable SeraCare to more fully meet the needs of these diagnostic researchers, fueling their innovation by providing reliable and qualified materials for use in these assays."
KPL's portfolio of products includes immunochemicals for in-vitro diagnostics, including primary and secondary antibodies as well as reagents and kits targeting ELISA, Western blotting, immunohistology, protein labeling, nucleic acid labeling, sample preparation, protein purification and recombinant protein detection and analysis.
These products reportedly "will support SeraCare's expansion from its core strength of providing biological products and control materials for infectious disease, women's health, and genetic testing into oncology, autoimmune, allergy and companion diagnostics," according to SeraCare
"SeraCare is an ideal fit for KPL, bringing two product offerings together under one company, and positioning us well to reach a broader audience within the diagnostic market," said Albert Perry, president and CEO of KPL. "Our product portfolios, research and development, and manufacturing expertise are complementary and will enable us to deliver a full suite of capabilities to the diagnostics market."
SeraCare secured funding for the acquisition and refinanced its existing debt with Madison Capital Funding and BB&T Capital Partners, and the company said this new financing relationship strengthens SeraCare's capital base for future growth both organically and through additional acquisitions.